An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody

Sponsor
Tianjin Medical University Cancer Institute and Hospital
Study ID
NCT04866381
Phase
PHASE2
Status
Unknown

Conditions

  • Esophageal Squamous Cell Carcinoma
  • Progression to PD-1 Antibody

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This study is being conducted to explore the efficacy of SHR-6390 and SHR-1020 in the treatment of esophageal squamous cell carcinoma after progression on PD-1 Antibody.

Key Dates

Start date
Apr 30, 2021
Status verified
Apr 2021
Primary completion
Apr 30, 2023
Completion
Apr 30, 2023

Study Design

Enrollment
87 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-6390
    SHR-6390
  • Experimental: SHR-6390 combined with Camrelizumab (SHR-1210)
    SHR-6390 combined with Camrelizumab (SHR-1210)
  • Experimental: Camrelizumab (SHR-1210) combined with SHR-1020
    Camrelizumab (SHR-1210) combined with SHR-1020

Primary Outcome Measure

Objective Response Rate [ Time Frame: 1 year ]

Related Studies